Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.